Maxi-K + channels in vascular smooth muscle cells play a major vasodilator role in the regulation of arterial tone because their activation by cytosolic Ca 2+ produces a membrane hyperpolarization that opposes to myocyte contraction. 1 Vascular maxi-K + channels are composed of the pore-forming α-subunits, and auxiliary β1-subunits, which increase severalfold the affinity of the channels for Ca 2+ . [2] [3] [4] Mice deficient of the maxi-K + β1-subunit exhibit uncoupling of Ca 2+ sparks to maxi-K + channel activation in vascular smooth muscle cells, 5 and develop systemic hypertension and cardiac hypertrophy. 5, 6 Downregulation of maxi-K + β1-subunit has been reported in rats made hypertensive after chronic treatment with angiotensin II, 7 and a single-nucleotide polymorphism in the human maxi-K + β1 gene (KCNMB1) has been found to be associated with low prevalence of diastolic hypertension. 8 Recently, we have shown in rat and human arterial myocytes that hypoxia (or a hypoxia/reoxygenation sequence) downregulates the expression of the β1-subunit and decreases the vasorelaxing force of maxi-K + channels. 9 We hypothesized that in patients with obstructive sleep apnea-hypopnea syndrome (SAHS) β1-subunit expression is modulated by the level of chronic intermittent hypoxemia, and thus participates in the cardiovascular complications of the disease. The SAHS is characterized by complete or partial interruption of airflow during sleep due to pharyngeal collapse and affects 2% of women and 4% of men of the general population. 10 Several epidemiological studies have demonstrated that untreated SAHS patients have high rates of hypertension and consequent cardiovascular morbidity and mortality, [11] [12] [13] [14] [15] [16] and the risk of these complications was reduced after correction of nocturnal hypoxemia with continuous positive airway pressure (CPAP). 15, 17, 18 SAHS is considered an independent risk factor for hypertension, and it has been identified as a cause of secondary hypertension in the seventh report of the Joint National Committee as well as in the guidelines of the European Society of Hypertension and the European Society of Cardiology. 19, 20 Nevertheless, the mechanisms underlying the association between SAHS and hypertension are not well understood. 14, 21, 22 We have performed a pilot study to analyze the relationships among hypoxia, arterial pressure, and the 
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Methods
We studied 20 male patients with strong clinical suspicion of SaHS. Overnight polysomnography and 24-h ambulatory blood pressure monitoring were performed in each patient. Evaluation of β1-subunit mRNa expression was made by a simple blood test using peripheral blood leukocytes (PBLs). The last two determinations were repeated 3 months after initiation of continuous positive airway pressure (CPaP) treatment.
results
In untreated obstructive SaHS patients, β1-subunit mRNa levels were correlated with the minimum level of overnight blood O 2 saturation (r 2 = 0.56, P < 0.05) and systolic arterial pressure (r 2 = 0.64, P < 0.01). Notably, the correction of nocturnal hypoxemia with CPaP resulted in upregulation of β1-subunit mRNa and to a parallel significant decrease of systolic and diastolic arterial pressures of 6.5 and 5.3 mm Hg, respectively. conclusions These observations, although preliminary, suggest that the maxi-K + β1-subunit could contribute to vascular dysregulation in SaHS patients. Leukocyte β1 expression may be an independent readout of hypoxemia that could be useful as molecular marker for impending hypertension. expression of the β1-subunit in patients with SAHS, and to determine whether changes in oxygen saturation and arterial pressure are associated to modifications of β1 expression after CPAP treatment. We have developed a blood test to monitor β1-subunit mRNA expression using human peripheral blood leukocytes (PBLs).
Methods
Selection and studies on SAHS patients. We studied 20 consecutive patients attended for the first time in the Sleep Unit of our institution that met the inclusion criteria. They were men aged between 35 and 65 years, with strong clinical suspicion of SAHS (chronic snoring, frequent respiratory pauses as reported by their partner, and excessive daytime sleepiness). We excluded from the study patients with antihypertensive and other vascular-targeted medication, basal arterial PO 2 < 70 mm Hg or that had suffered stroke or coronary heart disease. Other entities such as liver disease, renal disease, diabetes, and anemia were ruled out by laboratory screening. Patients suffering an acute infection or having a job that implied risk related with excessive daytime somnolence were also not recruited. The study was approved by the local Ethics Committee and written informed consent was obtained from each participant prior to inclusion in the study.
After admission in the study, each patient was subjected to 24-h ambulatory blood pressure (ABP) monitoring 11, 23 and to overnight polysomnographic analysis. ABP monitoring was performed using the Spacelabs 90207 device (Spacelabs, Redmond, WA) in the first 3 days after the polysomnographic study. The recording was done every 20 min starting at 9.00 am and lasting for a period of 24 h. All subject-activated readings were eliminated in order to homogenize the number of measurements. The patients were advised to avoid exercise or any activity greater than the usual, which might alter blood pressure or its circadian rhythm. To characterize the pattern of awake and nocturnal blood pressure, subjects recorded in a diary the time at which they went to sleep and awoke. In APB monitoring the following parameters were assessed: 24-h mean systolic and diastolic blood pressure; mean diastolic and systolic blood pressure during daytime and night time periods; and abnormal readings' percentage of systolic (>135 mm Hg) or diastolic (>85 mm Hg) blood pressure.
The overnight sleep study consisted of continuous polygraphic recordings from 22:00 pm to 7:00 am using standard equipment (SleepLab 1000P; Jaeger, Würzburg, Germany) with surface leads for electroencephalogram (C4/A1, C3/A2), electrooculogram, submental electromyogram, and electrocardiogram. Airflow was estimated by nasal cannula and by nasal and oral thermistors. Chest and abdominal efforts were measured by two belt sensors. Arterial oxygen saturation was recorded by digital pulse oximeter. Baseline arterial oxygen saturation was measured while the patient was awake (baseline Sat O 2 ) and the nadir arterial oxygen saturation levels were obtained (Min Sat O 2 ). All the recordings were analyzed manually. In the polysomnographic analysis the following events were defined: (i) apnea: a complete cessation of oronasal airflow for at least 10 s; (ii) hypopnea: a ≥50% reduction in the oronasal airflow lasting ≥10 s and accompanied by a desaturation and/ or an electroencephalographic arousal; (iii) desaturation: a decrease of 4% from the pre-event level in arterial oxygen saturation; and (iv) arousal: according to the recommendations of the American Sleep Disorders Association. 24 Sleep data were staged according to the system of Rechtschaffen and Kales. 25 To quantify overall nocturnal desaturation, we used the cumulative percentages of sleep time spent at saturations below 90% (CT 90 ). The apnea-hypopnea index (AHI) was defined as the number of apneas-hypopneas per hour of sleep, the desaturation index as the number of desaturations per hour of sleep, and the arousal index as the number of arousals per hour of sleep. The patients underwent a second polysomnography for CPAP titration within a maximum period of 2 weeks after the diagnostic sleep study. The starting level was 4 cm H 2 O and this pressure was increased by 1 cm H 2 O every 5 min until apneas disappeared. Then, CPAP level was progressively increased by 1 cm H 2 O steps every 10 min, until hypopneas, desaturations, and snoring disappeared. This pressure was considered to be the optimal CPAP.
Patients were subjected to CPAP treatment with the optimal pressure obtained. Objective CPAP compliance (assessed with objective monitors of CPAP used at the prescribed pressure (hourly counters)), 24-h ABP monitoring, as well as PBL β1 mRNA expression, were evaluated 3 months after initiation of treatment.
Cell cultures and hypoxic treatments. Square pieces (~3-mm side) of internal mammary arteries (from a separate group of patients who had undergone coronary artery bypass graft surgery 9 ) were cultured using the explant method. 9 Attached cells, which migrated from the human vascular specimens, were retrieved by using 0.25% trypsin/EDTA. Cells were cultured in Dulbecco's modified Eagle's medium with 20% fetal bovine serum, 25 mmol/l HEPES, 4.5 g/l glucose, 4 mmol/l l-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. Experiments were performed on 80%-confluent monolayers at passages 3-8. PBLs from normal subjects were obtained using CPT Cell Preparation Tubes (Becton Dickinson Vacutainer Systems, Franklin Lakes, NJ) following the manufacturer's indications. The Jurkat cell line was obtained from American Type Culture Collection (Middlesex, UK). When incubated, both cell types were maintained in RPMI 1640 (Roswell Park Memorial Institute, Buffalo, NY) medium with 10% fetal bovine serum. Cultured cells were maintained in complete medium in a normoxic atmosphere (95% air/5% CO 2 ) at 37 °C (ThermoForma 3121 incubator; Forma Scientific, San Bruno, CA). Complete medium was replaced at the start of each experiment. Twenty-four-hour hypoxia exposure was done in an incubator with oxygen control (ThermoForma 3141 incubator, Forma Scientific) with 1% O 2 and 5% CO 2 , balanced N 2 . Oxygen levels were monitored by a Fyrite Gas Analyzer (Brigon Messtechnik, Rodgau, Germany).
RNA analysis. Total RNA from cultured mammary artery myocytes and Jurkat cells was isolated following the NucleoSpin articles β1 Modulation in Sleep Apnea Patients RNA II kit method. Total RNA from fresh human PBLs was isolated in the first hour after blood collection following the QIAamp RNA Blood Mini kit. For reverse transcription (RT) of RNA we followed the instructions of Superscript III FirstStrand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA). Total RNA (0.25 µg) was used in each 60-µl reaction mixture. Oligonucleotide primers for conventional and realtime quantitative PCR are described below. Quantitative PCRs were performed with the Brilliant SYBR Green QPCR Master mix (Stratagene, La Jolla, CA) in a 15-µl reaction mixture containing 1× Brilliant SYBR Green QPCR Master mix, 250-500 nmol/l primers, and 0.5 µl (or 1/10 dilution in the case of 28S amplification) of the final RT volume. Real-time PCRs were run on an Mx3005P (Stratagene) device using the following program: 10 min at 95 °C, 40 cycles of 15 s at 95 °C, and 1 min at 60 °C. The primers used were (5′ to 3′): (i) human β1 maxi-K (NM_004137) forward, GTGTGCCGTCATCACCTACTACAT (nucleotides 475-498); reverse, CCTGGGTCCACACGCTTT (nucleotides 531-548); (ii) Human 28S rRNA (M11167) forward, GTGACGCGCATGAATGGA (nucleotides 3733-3790); reverse, CCCTTGGCTGTGGTTTCG (nucleotides 3827-3844). The PCR products were analyzed by using Mx3005P v2.02 software for real-time PCR. Melting curve analysis showed a single sharp peak with the expected temperature of melting for all samples. Quantification was performed by interpolation using the standard regression curve of C t values generated from the final RT volume. For confirmation of β1 transcript levels we used a TaqMan probe as previously described. 9 Statistical analysis. Data are expressed as mean ± s.e. with the number (n) of experiments indicated. Paired t-test was performed for the pre-post CPAP analysis and for the ex vivo cell studies. Relation among the variables was tested by single regression analysis. The correlation was analyzed by Pearson's coefficient. A linear regression model was constructed stepwise to establish the relationship between β1 expression and the rest of variables. A value of P < 0.05 was considered statistically significant.
results
As biopsies of human arterial smooth muscle are not feasible, we first investigated whether the maxi-K + β1-subunit is expressed in human PBLs and is regulated by hypoxia. PBLs were chosen for the study because they can be routinely obtained from patients and are in direct contact with blood O 2 . In both fresh PBLs and Jurkat cells (a human T-lymphocyte cell line), a band of the same size as the β1 mRNA of human mammary artery was identified by RT-PCR (Figure 1a) . β1 mRNA identity was further confirmed by sequencing the PCR fragments. As in arterial myocytes, 9 exposure to hypoxia (Figure 1b) . These data suggested that PBL β1 mRNA level, downregulated by hypoxia as in smooth muscle cells, can be used as a read out of vascular β1 mRNA modulation by O 2 tension. Next, we systematically tested β1 mRNA levels in PBLs of 20 untreated SAHS patients. They were male, aged 47.3 ± 1.9 years, and with body mass index (BMI) of 33 ± 0.8 kg/ m 2 . Laboratory screening showed an increased mean of total cholesterol (228.9 ± 7.9 mg/dl). Transaminases, creatinine, glycated hemoglobin (HbA1c), and hemoglobin were in the normal range.
The values of the parameters measured during individual overnight sleep studies and 24-h ABP monitoring are shown in Table 1 . As expected by the clinical features required for the patients to be included in the study, the AHI was high (65.5 ± 4.8), indicating that the patients suffered severe SAHS. Although means of systolic and diastolic blood pressures were <140 and <90 mm Hg, respectively, 7 of the 20 patients (35%) had elevated 24-h ABP. The level of expression of β1-subunit mRNA in PBLs evaluated as threshold cycle (C t ) of amplification by real-time quantitative PCR was 27.6 ± 0.4 with a range between 24.8 and 31.
When relations among the variables were analyzed, we observed a significant inverse correlation between mean 24-h systolic arterial pressure and the minimum level of overnight arterial O 2 saturation (an indication of the severity of the sleep-disordered breathing) (Figure 1c) . This last parameter was directly correlated with the β1 mRNA levels in PBLs (Figure 1d) . In consequence, a close correlation (r 2 = 0.64; P < 0.01) was observed when β1 mRNA levels were plotted against systolic arterial pressure (Figure 1e) . No significant correlation was found between β1-subunit mRNA level or blood pressure and either CT 90 , AHI, or arousal index.
The relationship between hypoxia and β1 mRNA expression may be confounded by different variables. First, it should be taken into consideration that all patients were male and that none of them were being treated with antihypertensive medication or other vascular-targeted pharmacological treatments. In these patients, in addition to minimum arterial oxygen saturation (Min Sat O 2 ), other variables (age, BMI, HbA1c, and total cholesterol) were evaluated. A bivariate correlation analysis considering all the variables showed statistical significance only for β1 expression (measured as β1 C t ) as a function of Min Sat O 2 (r = −0.75, P < 0.05). A statistical analysis using a multiple regression model confirmed that there was only significant correlation (R 2 = 0.56; P < 0.05) between β1 C t and Min Sat O 2. The equation (R 2 = 0.91) for this model was: β1 C t = 30.10 − 0.11 Min Sat O 2 + 0.06 age + 0.02 BMI + 0.15 HbA1c + 0.01 total cholesterol. Thus, we have found no evidence that these factors were important confounders in our 20-patient series.
Patients were subjected to CPAP treatment, and determination of PBL β1 mRNA expression as well as 24-h ABP monitoring was done 3 months after initiation of treatment. The mean of daily CPAP use for the 20 patients was uniformly high (5.72 ± 0.35 h) as expected in patients with severe SAHS. There was no correlation between CPAP compliance and any of the outcome variables. In our entire cohort (n = 20) the average BMI did not significantly change (33 ± 0.8 and 34 ± 0.8 kg/m 2 pre-vs. post-CPAP).
To evaluate the changes of β1 mRNA levels after correction of nocturnal hypoxemia, we calculated the β1 index (post-CPAP β1 mRNA/pre-CPAP β1 mRNA) for each patient. On average, CPAP produced a statistically significant increase in β1-subunit expression in the population studied (β1 index = 1.36 ± 0.17, n = 20) (Figure 2) . In parallel, CPAP treatment also resulted in 6.5 and 5.3 mm Hg mean decreases of systolic and diastolic blood pressures, respectively (Table 1 and Figure 2 ).
discussion
The results of this study suggest that the maxi-K + channel β1-subunit expression can be monitored by a simple blood test using human leukocytes. This has allowed us to demonstrate the existence of close relationships among blood de-oxygenation, leukocyte β1-subunit mRNA levels, and arterial tension in untreated SAHS patients. Notably, the correction of blood O 2 tension with CPAP was paralleled by both upregulation of β1-subunit mRNA and a pronounced decrease of systolic and diastolic arterial pressures.
Recent reports have indicated that CPAP reduces blood pressure in patients with SAHS, and that the benefit is larger in individuals with more severe nocturnal oxygen desaturation. 17, 18 In our pilot study we have observed a relation between hypoxemia and the level of β1 expression. Our regression model shows that the decrease in Min Sat O 2 was a predictor of β1 expression: each 10% of decrease in Min Sat O 2 increased the β1 C t in 1.1 (which means a 50% decreased of β1 mRNA quantity). Although this stepwise regression model includes other variables that have been previously ruled out in the relationship between hypertension and SAHS (age, BMI) as well as several additional variables (HbA1c, total cholesterol), the only one with statistical significance was the minimum level of overnight arterial O 2 saturation. It must be kept in mind, however, that besides O 2 tension, regulation of β1 mRNA expression surely depends on other uncontrolled factors 7, 26 that could determine the low responsiveness of β1 mRNA levels to CPAP treatment in some subjects. In addition, other proposed mechanisms underlying the association between SAHS and hypertension (such as the overactivity of the sympathetic nervous system or abnormalities in endothelial function) could have a more prominent role in some individuals. 27, 28 Within the context of this "Discussion" it might be worthy to stress that major individual differences in the molecular responsiveness (leukocyte β1 level) to CPAP were observed. Therefore, although the number of cases is obviously too small, a preliminary patient classification could be attempted depending on this parameter. We have previously documented that a 25% quantitative difference of the level of β1 expression in arteries has important effects on β1-dependent vascular regulation in myographic studies. 9 Considering as a functionally significant response an increment of 25% in the β1 mRNA (this is a β1 index > 1.25), our SAHS patients could be classified into "responder" (β1 index > 1.25; mean β1 index = 1.95 ± 0.2, n = 10) and "non-responder" (β1 index ≤ 1.25; mean β1 index = 0.82 ± 0.1, n = 10) classes. Whereas the changes of blood pressure after CPAP treatment were small and not statistically significant in "non-responder" subjects (2.7 ± 0.9 and 3.2 ± 1.3 mm Hg, respectively, n = 10), a marked, and highly statistically significant, decrease of systolic and diastolic pressures (9.6 ± 1.6 and 7.3 ± 1.4 mm Hg, respectively, n = 10) were observed in "responder" patients. This comparative analysis further supports the view that β1 mRNA levels correlate with blood pressure.
In spite of the dependence of β1-subunit mRNA levels on the magnitude of nocturnal hypoxemia, we did not detect any correlation between β1-subunit expression and other polysomnographic variables (such as the AHI or the arousal index). These findings could be explained by the fact that all our patients had severe SAHS, so differences among them were difficult to establish except for those specific indexes more directly reflecting arterial oxygenation. Moreover, animal studies have suggested that arousals from sleep only cause transient hypertension and that sustained hypertension in SAHS is mainly related to intermittent nocturnal hypoxemia. [29] [30] [31] The absence of correlation of CPAP compliance with any of the outcome variables, including the ratio of β1 expression and the change of arterial pressure (post-CPAP vs. pre-CPAP) could be explained by the fact that in the whole series objective CPAP compliance was uniformly high, as it is expected in patients with severe SAHS.
Several studies have reported a high prevalence (50-70%) of hypertension in SAHS patients. 32, 33 In our entire cohort of severe SAHS patients (AHI of 65.5), prevalence of hypertension (35%) is lower than reported and average arterial pressure values were within normal range ( Table 1) . These facts are probably explained because patients with antihypertensive treatment were excluded.
Our study is restricted to a limited cohort of selected untreated SAHS patients, with relatively severe sleep-disordered breathing but still with minor cardiovascular affectation, and we have not attempted to investigate whether in this cohort β1 expression is downregulated with respect to healthy subjects. However, the existence of close relationships among oxygenation level, leukocyte β1-subunit mRNA expression, and arterial tension in untreated subjects, as well as the effect of CPAP treatment on these parameters suggest that maxi-K + channel β1-subunit contributes to vascular dysregulation in SAHS patients. Future studies on a large series of normal subjects as well as in individuals with SAHS randomly treated with CPAP or "sham CPAP" with a broad spectrum of disease severity should be performed to clarify definitively the pathophysiology of SAHSderived hypertension. Moreover, the relationship between β1 expression in leukocytes and vascular smooth muscle has not been completely established. Human vascular smooth muscle cannot be biopsed, so it is not possible to measure the level of maxi-K + channel expression in vascular smooth muscle of sleep apnea patients. Thus, we used peripheral leukocytes as a surrogate of vascular smooth muscle because, in terms of hypoxia responsiveness, the maxi-K + β1 mRNA in leukocytes (PBLs and Jurkat cells) exhibit the same response as the maxi-K + channel β1 mRNA in human vascular smooth muscle. 9 Modulation of leukocyte maxi-K + β1 mRNA by O 2 tension was also confirmed in our in vivo pilot study since correction of hypoxia with CPAP treatment was paralleled by decrease of arterial pressure and upregulation of β1-subunit mRNA. However, further animal studies demonstrating a correlation between β1 expression in leukocytes and vascular smooth muscle, including the protein level, are necessary to confirm our hypothesis.
In conclusion, our study, although preliminary and in some aspects speculative, suggests the existence of association among the maxi-K + channel β1-subunit, a protein expressed in the cardiovascular system involved in the development of hypertension, [5] [6] [7] [8] [9] and sleep apnea; thus providing a possible mechanistic explanation whereby in SAHS patients chronic intermittent hypoxia might lead to cardiovascular disease. Additionally, our observations indicate that the level of β1 expression in PBLs is an independent readout of hypoxemia and a molecular marker that could be of use to diagnose impending hypertension and to predict vascular responsiveness to CPAP in SAHS patients. This last aspect could be clinically important because asymptomatic individuals with SAHS often have difficulties to comply with CPAP treatment in absence of perceived benefits, and a simple test with peripheral leukocytes might identify patients who are at risk to develop hypertension and probably respond to treatment. 
